Search

Your search keyword '"Weitzman, Aaron"' showing total 9 results
Start Over Author "Weitzman, Aaron" Publisher american society of clinical oncology (asco)
9 results on '"Weitzman, Aaron"'

1. Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.

Author

Morelli, Maria Pia, primary, Negrao, Marcelo Vailati, additional, Collinson-Pautz, Matthew R., additional, Jernigan, Kamisha, additional, Demars, Nathan A., additional, Weitzman, Aaron, additional, Adeyemi, Frances, additional, Carpio, Victor H, additional, Jazaeri, Amir A., additional, Johnson, Benny, additional, Pant, Shubham, additional, Kebriaei, Partow, additional, Srivastava, Abhishek K, additional, Deniger, Drew Caldwell, additional, Heymach, John, additional, and Kopetz, Scott, additional

Published
2023
Full Text
View/download PDF

2. First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).

Author

Bendell, Johanna C., primary, Fong, Lawrence, additional, Stein, Mark N., additional, Beer, Tomasz M., additional, Ross, Ashley, additional, Gao, Xin, additional, Weitzman, Aaron, additional, Austin, Richard, additional, Ganti, Vaishnavi, additional, Law, Che-Leung, additional, Lemon, Bryan, additional, Wesche, Holger, additional, and De Bono, Johann S., additional

Published
2020
Full Text
View/download PDF

3. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Author

Smith, Matthew, primary, De Bono, Johann, additional, Sternberg, Cora, additional, Le Moulec, Sylvestre, additional, Oudard, Stéphane, additional, De Giorgi, Ugo, additional, Krainer, Michael, additional, Bergman, Andries, additional, Hoelzer, Wolfgang, additional, De Wit, Ronald, additional, Bögemann, Martin, additional, Saad, Fred, additional, Cruciani, Giorgio, additional, Thiery-Vuillemin, Antoine, additional, Feyerabend, Susan, additional, Miller, Kurt, additional, Houédé, Nadine, additional, Hussain, Syed, additional, Lam, Elaine, additional, Polikoff, Jonathan, additional, Stenzl, Arnulf, additional, Mainwaring, Paul, additional, Ramies, David, additional, Hessel, Colin, additional, Weitzman, Aaron, additional, and Fizazi, Karim, additional

Published
2016
Full Text
View/download PDF

4. Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Author

Smith, Matthew Raymond, primary, De Bono, Johann Sebastian, additional, Sternberg, Cora N., additional, Le Moulec, Sylvestre, additional, Oudard, Stephane, additional, De Giorgi, Ugo, additional, Krainer, Michael, additional, Bergman, Andre M., additional, Hoelzer, Wolfgang, additional, De Wit, Ronald, additional, Boegemann, Martin, additional, Saad, Fred, additional, Cruciani, Giorgio, additional, Thiery- Vuillemin, Antoine, additional, Feyerabend, Susan, additional, Miller, Kurt, additional, Ramies, David Albert, additional, Hessel, Colin, additional, Weitzman, Aaron, additional, and Fizazi, Karim, additional

Published
2015
Full Text
View/download PDF

5. Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

Author

Basch, Ethan M., primary, Scholz, Mark C., additional, De Bono, Johann Sebastian, additional, Vogelzang, Nicholas J., additional, De Souza, Paul L., additional, Marx, Gavin M., additional, Vaishampayan, Ulka N., additional, George, Saby, additional, Schwarz, James K., additional, Antonarakis, Emmanuel S., additional, O'Sullivan, Joe M., additional, Rezazadeh Kalebasty, Arash, additional, Chi, Kim N., additional, Dreicer, Robert, additional, Hutson, Thomas E., additional, Mangeshkar, Milan, additional, Holland, Jaymes S., additional, Weitzman, Aaron, additional, and Scher, Howard I., additional

Published
2015
Full Text
View/download PDF

7. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort.

Author

Scher, Howard I., primary, Smith, Matthew R., additional, Sweeney, Christopher, additional, Corn, Paul Gettys, additional, Logothetis, Christopher, additional, Vogelzang, Nicholas J., additional, Smith, David C., additional, Hussain, Maha, additional, George, Daniel J., additional, De Bono, Johann Sebastian, additional, Higano, Celestia S., additional, Small, Eric Jay, additional, Goldin, Jonathan, additional, Brown, Matthew S., additional, Aftab, Dana T., additional, Noursalehi, Mojtaba, additional, Weitzman, Aaron, additional, and Basch, Ethan M., additional

Published
2013
Full Text
View/download PDF

8. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Author

Smith, David C., primary, Smith, Matthew R., additional, Sweeney, Christopher, additional, Elfiky, Aymen A., additional, Logothetis, Christopher, additional, Corn, Paul G., additional, Vogelzang, Nicholas J., additional, Small, Eric J., additional, Harzstark, Andrea L., additional, Gordon, Michael S., additional, Vaishampayan, Ulka N., additional, Haas, Naomi B., additional, Spira, Alexander I., additional, Lara, Primo N., additional, Lin, Chia-Chi, additional, Srinivas, Sandy, additional, Sella, Avishay, additional, Schöffski, Patrick, additional, Scheffold, Christian, additional, Weitzman, Aaron L., additional, and Hussain, Maha, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results